A3 Adenosine Receptor Antagonists

Author: Muller C.E.

Source: Mini Reviews in Medicinal Chemistry, Volume 1, Number 4, November 2001 , pp. 339-348(15)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

During the past years a number of potent and selective antagonists for the human A3 adenosine receptor (AR) have been developed, including tricyclic compounds, such as triazoloquinazoline, pyrazolo-triazolopyridine, imidazopurinone, triazoloquinoxaline and pyrazoloquinoline derivatives. Bicyclic compounds include isoquinoline and related quinazoline derivatives. Monocyclic dihydropyridine and pyridine derivatives also proved to be potent selective A3 AR antagonists. So far, no potent, selective antagonist is available for rodent A3 ARs. Most of the A3 AR antagonists are highly lipophilic and exhibit very poor water-solubility. Potential therapeutic applications for A3 AR antagonists include inflammatory diseases, asthma, stroke, and glaucoma.

Keywords: Adenosine Receptor Antagonists; Imidazo purin-5-ones; Xanthines; Triazoloquinazolines; Pyrazolo-triazolo-pyrimidines; Pyrrolo pyrimidines (7-deazaade-nines); 1,4-Dihydropyridines, Pyridines; Pyrans; Flavonoids

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389557013406684

Publication date: 2001-11-01

More about this publication?

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.